[Corporal fat distribution and lipidic and glicemic profiles of HIV-infected patients].
The aims of this study were to describe anthropometric data and glycemic and lipidic profiles of HIV-infected patients treated or not with antiretrovirals (ARV) drugs, and to assess association between these drugs and body composition changes, lipid and glucose homeostasis disturbances. There were 176 patients included (133 ARV-treated patients and 43 ARV-naïve). The patients were submitted to clinical evaluation, laboratorial analysis, ultrasonographic measurements, bioelectrical impedance analysis and skin folds thickness measurements. The ARV-treated group showed higher waist-to-hip ratio (p= 0.0002), higher intra-abdominal fat thickness measured by ultrasonography (p= 0.003) and lower bicipital (p= 0.01) and tricipital (p= 0.0002) skin folds. This group also showed higher triglyceride (p= 0.0002), total cholesterol (p= 0.00007), HDL cholesterol (p= 0.009), glucose measurements one hour (p= 0.01) and two hours (p= 0.001) after dextrose load, higher levels of fasting insulin (p= 0.03) and higher HOMAR index (p= 0.02). The antiretroviral drugs are associated with increased visceral fat and decreased peripheral fat pads. Beside that, these drugs are associated with atherogenic lipid profile and insulin resistance, two independent risk predictors of cardiovascular disease.
Guimarães
Milena Maria M
MM
Departamento de Clínica Médica, Faculdade de Medicina, UFMG, Belo Horizonte, MG. milenamg@uol.com.br
Greco
Dirceu Bartolomeu
DB
de O Júnior
Antônio Ribeiro
AR
Penido
Mariana Guimarães
MG
Machado
Lucas José de C
LJ
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D001786:Blood Glucose / Q000187:drug effects*; D050218:Body Fat Distribution; D015992:Body Mass Index; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000378:metabolism; D006801:Humans; D050152:Intra-Abdominal Fat / Q000187:drug effects; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced / Q000378:metabolism; D008875:Middle Aged; D018709:Statistics, Nonparametric; D050507:Subcutaneous Fat, Abdominal / Q000187:drug effects
D019380:Anti-HIV Agents; D001786:Blood Glucose